LONDON, UK / ACCESSWIRE / February 25, 2021 / 2020 has been a memorable year for Ryvu. Menarini, the partner sponsoring SEL24/MEN1703 development, completed the Phase I part of the Phase I/II trial in acute myeloid leukaemia (AML) and presented the first ever data with an in-house developed asset. In April 2020, Ryvu signed a discovery agreement in inflammatory diseases with Galapagos. Ryvu could receive up to €53.5m (€1.5m paid upfront). On the internal R&D front, the company has terminated two preclinical stage projects for strategic reasons (A2A/A2B antagonist and SMARCA2 inhibitor) and submitted a clinical trial application to start a new Phase I/II trial with SEL120 in solid tumours. Notably, the FDA granted an orphan drug designation for SEL120 in AML in March 2020. The share issue in July 2020 will support existing plans for the next two years. Our updated valuation of Ryvu is PLN1.17bn or PLN63.6/share vs PLN68.9/share previously.
Our valuation of Ryvu is PLN1.17bn or PLN63.6/share, vs PLN1.10bn or PLN68.9/share previously. The R&D assumption changes had a slight net negative effect, which was partially offset by higher net cash after the recent share issue. The main changes include the removal of the A2A/A2B antagonist and SMARCA2 inhibitor projects, while we have added a new indication - TNBC - for SEL120.
Click here to view the full report or here to sign up to receive research as it is published.
All reports published by Edison are available to download free of charge from its website
www.edisongroup.com
About Edison: Edison is a leading research and investor relations consultancy, connecting listed companies to the widest pool of global investors. By focusing on the volume and quality of investors reached - across institutions, family offices, wealth managers and retail investors - Edison can create and gauge intent to purchase, even in the darkest pools of capital, and then make introductions via non-deal roadshows, events or virtual meetings.
Having been the first in-market 17 years ago, Edison now has more than 100 analysts covering every economic sector. Headquartered in London, Edison also has offices in New York, Frankfurt, Amsterdam and Tel Aviv and a presence in Athens, Johannesburg and Sydney.
Edison is authorised and regulated by the Financial Conduct Authority.
Edison is not an adviser or broker-dealer and does not provide investment advice. Edison's reports are not solicitations to buy or sell any securities.
For more information, please contact Edison:
Jonas Peciulis +44 (0)20 3077 5728 healthcare@edisongroup.com
Learn more at www.edisongroup.com and connect with Edison on:
LinkedIn https://www.linkedin.com/company/edison-group-/
Twitter www.twitter.com/Edison_Inv_Res
YouTube www.youtube.com/edisonitv
SOURCE: Edison Investment Research Limited
View source version on accesswire.com:
https://www.accesswire.com/631623/Ryvu-Therapeutics-RVU-Rebalancing-RD-Pipeline-Towards-Clinical-Stage
